Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Context Therapeutics Inc. - Common Stock (NQ:CNTX)

2.295 -0.035 (-1.50%)
Streaming Delayed Price Updated: 9:32 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Context Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Insiders Buying AmeriServ Financial And 2 Other Penny Stocks ↗
The Dow Jones dropped by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... 
Via Benzinga
News headline image
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Why TransCode Therapeutics Shares Are Trading Higher By 42%; Here Are 20 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Tesla, Amazon, Apple, Context Therapeutics, Snap: Why These 5 Stocks Are Drawing Investors' Attention Today ↗
Major Wall Street indices closed over 1% higher on Tuesday, led by upbeat corporate earnings and expectations that the Federal Reserve will slow down its rate hike pace as the centr 
Via Benzinga
News headline image
Dow Surges Over 200 Points; Pfizer Issues Weak Forecast ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Tuesday. The Dow traded up 0.63% to 33,931.13 while the NASDAQ rose 1.20% to 11,529.99. The S&P... 
Via Benzinga
News headline image
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Why Context Therapeutics (CNTX) Shares Are Seeing Blue Skies ↗
Context Therapeutics Inc (NASDAQ: CNTX) shares are trading higher by 60.32% to $1.10 Tuesday afternoon after the company announced its clinical trial collaborator, Stemline Therapeutics, received... 
Via Benzinga
News headline image
Dow Turns Higher; Nasdaq Jumps 100 Points ↗
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Tuesday. The Dow traded up 0.19% to 33,781.23 while the NASDAQ rose 0.90% to 11,496.13. The S&P... 
Via Benzinga
News headline image
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
$1 Million Bet On Motorsport Games? Check Out These 4 Penny Stocks Insiders Are Buying ↗
The Nasdaq dropped more than 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... 
Via Benzinga
News headline image
Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying ↗
The Dow Jones closed higher by more than 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
News headline image
Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying ↗
The Dow Jones closed lower by more than 600 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
News headline image
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Why Context Therapeutics Stock Is Falling 25% Today ↗
Context Therapeutics Inc (NASDAQ: CNTX) shares are trading lower by 26.62% to $1.02 during Thursday's session after the company reported preliminary Phase 2 data for ONA-XR metastatic breast cancer.... 
Via Benzinga
News headline image
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split. 
Via Benzinga
News headline image
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presented 
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Partners With Integral Molecular To Develop An Emerging Cancer Drug ↗
Context Therapeutics Inc. (NASDAQ: CNTX) and Integral Molecular are teaming up to develop an anti-claudin 6 (CLDN6) bispecific monoclonal antibody (BsMAb) for cancer therapy.  
Via Benzinga
News headline image
Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
New Ammo In The Battle Against Cancer – Context Therapeutics Sees Promising Results For Several Novel Drugs ↗
Martin Lehr, Co-Founder and CEO of Contect Therapeutics, Inc (NASDAQ: CNTX), was a guest on Benzinga’s All Access on Aug 12, 2022. 
Via Benzinga
News headline image
69 Biggest Movers From Friday ↗
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
News headline image
40 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share. 
Via Benzinga
News headline image
35 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Aterian, Inc. (NASDAQ: ATER) shares jumped 43.5% to $3.3457. Aterian said Cynthia Williams has joined the Company's Board of Directors. Jumia Technologies AG (... 
Via Benzinga
News headline image
66 Biggest Movers From Friday ↗
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
If you're looking for the biggest pre-market stock movers for Monday, we've got you covered with a list of gainers and losers for today. 
Via InvestorPlace
News headline image
68 Biggest Movers From Yesterday ↗
Gainers GBS Inc. (NASDAQ: GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation. Aterian, Inc. (NASDAQ: ATER) shares... 
Via Benzinga
News headline image
26 Stocks Moving in Monday's Pre-Market Session ↗
Gainers SPI Energy Co., Ltd. (NASDAQ: SPI) rose 36.3% to $3.87 in pre-market trading after reporting record revenue of $162 million for 2021. Twitter, Inc. (NYSE: TWTR) rose... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022 ↗
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.